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ActR = activin receptor; Alk = activin receptor-like kinase; BMP = bone morphogenetic protein; BMPR = bone morphogenetic protein receptor;
FPPH = familial primary pulmonary hypertension; PPH = primary pulmonary hypertension; TGF = transforming growth factor.
Available online http://respiratory-research.com/content/2/4/193
Introduction
The diagnosis of PPH is made in the presence of an
increase in pulmonary vascular resistance associated with
right ventricular failure in the absence of any other disease
process. The etiology and primary cellular targets of this
disease are unknown, although pathologic studies indicate
that the disease is confined to the pulmonary vasculature.
PPH is characterized by several well defined structural
lesions: increased medial and adventitial thickness,
appearance of muscle in smaller and more peripheral
arteries than normal, reduction in number of peripheral
arteries, eccentric and concentric intimal thickening, and
plexiform lesions.
The disease is most commonly sporadic, but may also
be associated with an autosomal-dominant mode of
inheritance (FPPH) in 6% of patients [1]. Both forms of
the disease have an identical phenotype, and exhibit
preponderance in females of childbearing age. FPPH
families also show a pattern of incomplete penetrance,
in which only 10–20% of family members actually
develop overt disease. This has implications for our
understanding of the genetic and environmental modi-
fiers of disease expression in this condition, and has
also added to the complexity of genetic mapping of
affected kindreds.
Several recent papers presented the cumulative results of
a 15-year, genome wide search for an inherited locus in
this disease. They demonstrate that both FPPH and spo-
radic PPH may have a common etiology that is associated
with the inheritance and/or spontaneous development of
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germline mutations in the BMPR-II gene [2–5], which was
initially mapped to a single locus on chromosome 2q31-
32 [6]. Those reports describe heterozygous germline
mutations in the BMPR-II gene in FPPH [2,4,5], and in a
significant proportion of patients with apparently sporadic
disease [3,4]. These findings indicate that mutations in the
open reading frame of the BMPR-II gene can be identified
in approximately 60% of FPPH families, and in 25% of
patients with no family history of overt disease. The greater
frequency of sporadic as compared with familial inherited
disease suggests that this genetic mechanism is a rela-
tively common finding in both forms of the disease, and
further suggests that BMPR-II signaling plays a critical role
in the maintenance of normal pulmonary vascular physiol-
ogy. The findings also raise a series of previously unpre-
dicted questions regarding the biology of this gene
product, and how mutations at this locus give rise to the
distinctive pulmonary vascular phenotype that is seen in
patients with PPH.
In the present commentary we focus principally on the sig-
nificance of these findings in the context of our current
understanding of BMP receptor biology, and relate the
data to our knowledge of inheritance patterns and disease
pathophysiology of PPH.
Bone morphogenetic proteins
BMPR-II is a ubiquitously expressed receptor for a family
of secreted growth factors termed BMPs. These proteins
are part of the transforming growth factor (TGF)-b super-
family, which includes the three mammalian TGF-b iso-
forms, the activins and inhibins, and over 30 members of
the BMP subfamily [7,8]. Unlike the mammalian TGF-b iso-
forms, BMPs are secreted in an active form and, under
normal physiologic conditions, are regulated through
reversible interactions with extracellular antagonists,
including noggin, chordin, and DAN [9]. These interac-
tions determine the bioavailability of different BMPs for
binding to their cognate receptors and activation of down-
stream responses. BMPs themselves are further classified
into several subgroups on the basis of sequence similari-
ties and homology to common ancestral orthologs in fruit
flies. These include BMP-2 and BMP-4, which are most
closely related to the Drosophila gene product decapenta-
plegic; and BMP-5, BMP-6 and BMP-7, which are related
to Drosophila 60A.
Originally identified as molecules that induce ectopic bone
and cartilage formation when implanted subcutaneously in
rats [10], it is now known that BMPs are also critical regu-
lators of mammalian development [11]. For example, in the
lung BMP-4 and BMP-7 colocalize in the developing lung
buds, and targeted misexpression of BMP-4 [12] indi-
cates that it plays a critical role in embryonic lung morpho-
genesis. In contrast, little is known about the functional
properties of these proteins in the adult.
Bone morphogenetic protein receptors
Members of the TGF-b superfamily interact with two
classes of transmembrane receptor serine-threonine
kinases, termed type I and type II receptors [7,8]. The type
II receptors have constitutively active cytoplasmic kinase
domains, but are unable to activate downstream signals in
the absence of a type I receptor. In the case of BMPs this
involves the co-operative interaction between the ligands,
the type II receptors, BMPR-II, activin receptor (ActR)-II or
ActR-IIB, and the type I receptors TSk7L/activin receptor-
like kinase (Alk)2, BMPR-IA/Alk3 or BMPR-IB/Alk6.
Whereas the expression pattern of these receptors has
not been mapped in detail, it is known that BMPR-II is
widely expressed in both developing and adult mammalian
tissues [13,14].
Binding between the BMPs and the receptor complex is
determined both by the ligand–receptor binding affinities
and the local cell surface receptor expression levels of their
cognate receptors. For example, BMP-2, BMP-4 and BMP-
7 interact with and activate BMPR-IA/Alk3 and BMPR-
IB/Alk6 type I receptors, but only BMP-7 activates
signaling downstream of TSk7L/Alk2. The biology of this
system is further complicated by interaction of other TGF-b
family members with some of the same receptors as for the
BMPs. For example, activin has the capacity to activate
ActR-II- and ActR-IIB-dependent signaling, but unlike BMP-
2, BMP-4 and BMP-7 it only activates downstream signal-
ing through the type I receptor ActR-IB/Alk4 [15].
The physiologic significance of this combinatorial system
of receptor usage is poorly understood, but provides the
potential for marked plasticity in the regulation of down-
stream responses. This effect is further amplified because
a variety of downstream signaling pathways are activated
in a cell specific manner following engagement of the type
I and II receptors by BMPs. This includes not only activa-
tion of the canonical Smad signaling pathway [7,8], but
also cell-type-dependent activation of other signaling path-
ways, including TGF-b activated kinase 1 mediated p38
mitogen activated protein kinase [16,17] and protein
kinase A [18]. In addition, at a transcriptional level, differ-
ent inputs converge on a common regulatory mechanism
to define specific transcriptional responses. In the case of
Smad, this involves a complex interdependent interaction
between the BMP receptor activated Smads (Smad-1,
Smad-5 and Smad-8, the common-mediator Smad,
Smad-4) and a range of DNA binding transcription factors
and cofactors that are required to initiate a given transcrip-
tional response [19]. These various signaling pathways
are likely to provide an environment that enables cellular
diversity in response to a given set of ligand-receptor inter-
actions. Elucidation of these signals is fundamental to our
understanding of why mutations in a ubiquitously
expressed receptor give rise to a highly restricted pattern
of disease pathology in patients with PPH.c
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Bone morphogenetic receptor type II
mutations
To date, 46 different germline mutations in the BMPR-II
gene have been described in both FPPH and sporadic
PPH [2–5]. These span the entire open reading frame of
the BMPR-II gene, with the exception of exons 5, 10 and
13. The mutations include mis-sense and frameshift muta-
tions. The extent and heterogeneity of the BMPR-II muta-
tions identified thus far suggest that they are associated
with loss of expression and/or inactivation of the mutated
allelic products. However, no clear indication of how these
mutations give rise to PPH is readily apparent.
Theoretically, these mutations could be associated with
any or a combination of the following: simple haploid insuf-
ficiency resulting from the lack of BMPR-II protein expres-
sion or function; haploid insufficiency associated with a
secondary somatic mutational or regulatory event that
affects the remaining BMPR-II allele; and a more severe
disturbance in BMP signaling that results from dominant-
negative effects of the mutant receptor on BMPR-II signal-
ing. Loss-of-function mutations may result from defects in
RNA stability or protein processing associated with any
mis-sense or premature protein truncation mutations
[20,21]. Alternatively, a number of the BMPR-II mutations,
particularly the kinase domain truncations, could give rise
to dominant-negative receptors. Functional studies
[22–24] have shown that truncations and point mutations
in the kinase domain of BMPR-II, similar to those observed
in the FPPH families, exert dominant-negative effects on
BMP signaling.
It is of fundamental importance to define the functional
properties of these mutations, because they could have a
direct impact on severity of disease in affected families.
Furthermore, if the pulmonary phenotype in PPH is criti-
cally dependent on expression of both BMPR-II alleles,
then this raises the possibility that additional germline
mutations occur in regulatory elements from BMPR-II pro-
motor in the FPPH families with no identified mutation in
the BMPR-II open reading frame.
Genetics and pathophysiology of primary
pulmonary hypertension
Independent genetic and/or environmental effects are
likely to modify the cellular responses to the germline
mutations, and may be critical for the expression of PPH.
The relatively low disease penetrance of FPPH suggests
that its development probably requires additional environ-
mental and/or genetic events. Characterization of some of
the extended kindreds that harbor single BMPR-II muta-
tions [25] may facilitate identification of these additional
genetic or dominant environmental triggers. Another
feature of FPPH that may provide insight into these modi-
fier effects is the phenomenon of genetic anticipation [26].
This genetic phenomenon has been described in other
inherited diseases including Huntington’s chorea [27],
and is associated with the progressive accumulation of
trinucleotide repeats at selected loci in the genome.
Although there is currently no evidence for trinucleotide
repeats at the BMPR-II locus in FPPH, it is possible that
an alternative locus is affected by this phenomenon.
At present, we can only speculate about possible modifier
effects of different environmental and/or genetic influ-
ences in patients with PPH, and the functional properties
of different germline mutations. The key question of how
mutations of this ubiquitously expressed receptor predis-
pose individuals to develop isolated pulmonary vascular
disease remains mysterious and difficult to study. Homozy-
gous deletion of the BMPR-II gene in vivo is associated
with early embryonic lethality [28]. Furthermore, by the
time patients with PPH are symptomatic, the structural
changes of the disease are well developed, leaving us
with little clue as to which cell types form the primary
focus of vascular change in preclinical disease.
The arterial remodeling involves hypertrophy and prolifera-
tion of endothelial, smooth muscle and intimal cells, as
well as fibroblasts, but how defects in BMPR-II contribute
to these changes is not known. However, BMP-2 has
been shown to inhibit growth of cultured aortic vascular
smooth muscle cells [29,30], indicating they have intact
BMP signaling pathways, and that defects in BMP signal-
ing might predispose them to proliferate in an uncontrolled
manner under certain environmental conditions. Other
structural studies indicate that the plexiform lesions of
PPH are composed of monoclonal foci of proliferating
endothelial cells [31], and microdissection of endothelial
cells from these lesions resulted in microsatellite genomic
instability [32], which may give rise to spontaneous
somatic mutations. In the context of PPH, this might result
in the loss of the remaining BMPR-II allele in the affected
pulmonary vasculature, giving rise to a more complete
defect in BMP receptor signaling. However, although plex-
iform lesions are often considered pathognomonic of
PPH, they do not occur in all cases [33]. This indicates
that they are unlikely to represent the single common cel-
lular pathway of tissue injury in these patients.
Conclusion
Identification of germline BMPR-II gene mutations in
patients with FPPH and sporadic PPH has provided us
with an essential clue that will assist us in dissecting the
disease mechanisms and in determining which cell types
initiate and contribute to vascular remodeling in this
disease. Target cells probably express a program of
BMP receptors, ligands, and downstream signaling
machinery that make them uniquely susceptible to func-
tional defects in BMPR-II. For example, we have shown
that BMPR-II protein is expressed in human pulmonary
artery smooth muscle cells and in some endothelial cells
Available online http://respiratory-research.com/content/2/4/193(Fig. 1). Comparative analysis of components of the BMP
signaling pathway in different vascular beds will probably
lead to a better understanding of the unique properties of
the pulmonary vasculature, and facilitate the development
of selective animal models of BMPR-II dependent pul-
monary vascular injury.
References
1. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH,
Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et
al:  Primary pulmonary hypertension. A national prospective
study. Ann Intern Med 1987, 107:216–223.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III,
Loyd JE, Nichols WC, Trembath RC: Heterozygous germline
mutations in BMPR2, encoding a TGF-beta receptor, cause
familial primary pulmonary hypertension. The International
PPH Consortium. Nat Genet 2000, 26:81–84.
3. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert
M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman
J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A,
Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols
WC: Sporadic primary pulmonary hypertension is associated
with germline mutations of the gene encoding BMPR-II, a
receptor member of the TGF-beta family. J Med Genet 2000,
37:741–745.
4. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV,
Wheeler L, Phillips JA III, Newman J, Williams D, Galie N, Manes
A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert
M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath
RC, Nichols WC: BMPR2 haploinsufficiency as the inherited
molecular mechanism for primary pulmonary hypertension.
Am J Hum Genet 2001, 68:92–102.
5. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G,
Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge S,
E.Knowles JA: Familial primary pulmonary hypertension (gene
PPH1) is caused by mutations in the bone morphogenetic
protein receptor-II gene. Am J Hum Genet 2000, 67:737–744.
6. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND,
Siemieniak DR, Wheeler L, Phillips JA, Newman JH, Conneally
PM, Ginsburg D, Loyd JE: Localization of the gene for familial
primary pulmonary hypertension to chromosome 2q31-32.
Nat Genet 1997, 15:277–280.
7. Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regu-
lation in TGF-beta superfamily signaling. FASEB J 1999, 13:
2105–2124.
8. Kawabata M, Miyazono K: Skeletal Growth Factors. Philadelphia:
Lippincott Williams & Wilkins; 2000.
9. Reddi AH: Interplay between bone morphogenetic proteins
and cognate binding proteins in bone and cartilage develop-
ment: noggin, chordin and DAN. Arthritis Res 2001, 3:1–5.
10. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz
RW, Hewick RM, Wang EA: Novel regulators of bone forma-
tion: molecular clones and activities. Science 1988, 242:
1528–1534.
11. Hogan BL: Bone morphogenetic proteins: multifunctional reg-
ulators of vertebrate development. Genes Dev 1996, 10:
1580–1594.
12. Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan BL: Evi-
dence from normal expression and targeted misexpression
that bone morphogenetic protein (Bmp-4) plays a role in
mouse embryonic lung morphogenesis. Development 1996,
122:1693–1702.
13. Nohno T, Ishikawa T, Saito T, Hosokawa K, Noji S, Wolsing DH,
Rosenbaum, JS: Identification of a human type II receptor for
bone morphogenetic protein-4 that forms differential het-
eromeric complexes with bone morphogenetic protein type I
receptors. J Biol Chem 1995, 270:22522–22526.
14. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H,
Ten Dijke P, Heldin CH, Miyazono K: Cloning and characteriza-
tion of a human type II receptor for bone morphogenetic pro-
teins. Proc Natl Acad Sci USA 1995, 92:7632–7636.
15. Willis SA, Zimmerman CM, Li LI, Mathews LS: Formation and
activation by phosphorylation of activin receptor complexes.
Mol Endocrinol 1996, 10:367–379.
16. Shibuya H, Iwata H, Masuyama N, Gotoh Y, Yamaguchi K, Irie K,
Matsumoto K, Nishida E, Ueno N: Role of TAK1 and TAB1 in
BMP signaling in early Xenopus development. EMBO J 1998,
17:1019–1028.
Respiratory Research    Vol 2 No 4 De Caestecker and Meyrick
Figure 1
(A) Immunocytochemical localization of BMPR-II in the wall of a muscular pulmonary artery from control human lung. Localization (dark blue
product, BCIP/NBT) is seen in the smooth muscle cells (*) and occasional endothelial cells (arrowhead). (B) Control showing the same region of
artery, but without addition of antibody. Lu, lumen of artery.17. Monzen K, Shiojima I, Hiroi Y, Kudoh S, Oka T, Takimoto E,
Hayashi D, Hosoda T, Habara-Ohkubo A, Nakaoka,T, Fujita T,
Yazaki Y, Komuro I: Bone morphogenetic proteins induce car-
diomyocyte differentiation through the mitogen-activated
protein kinase kinase kinase TAK1 and cardiac transcription
factors Csx/Nkx-2.5 and GATA-4. Mol Cell Biol 1999, 19:
7096–7105.
18. Gupta IR, Piscione TD, Grisaru S, Phan T, Macias-Silva M, Zhou
X, Whiteside C, Wrana JL, Rosenblum ND: Protein kinase A is a
negative regulator of renal branching morphogenesis and
modulates inhibitory and stimulatory bone morphogenetic
proteins. J Biol Chem 1999, 274:26305–26314.
19. Massague J, Wotton D: Transcriptional control by the TGF-
beta/Smad signaling system. EMBO J 2000, 19:1745–1754.
20. Aridor M, Balch WE: Integration of endoplasmic reticulum sig-
naling in health and disease. Nat Med 1999, 5:745–751.
21. Hentze MW, Kulozik AE: A perfect message: RNA surveillance
and nonsense-mediated decay. Cell 1999, 96:307–310.
22. Liu F, Ventura F, Doody J, Massague J: Human type II receptor
for bone morphogenic proteins (BMPs): extension of the two-
kinase receptor model to the BMPs. Mol Cell Biol 1995, 15:
3479–3486.
23. Frisch A, Wright CV: XBMPRII, a novel Xenopus type II recep-
tor mediating BMP signaling in embryonic tissues. Develop-
ment 1998, 125:431–442.
24. Ishikawa T, Yoshioka H, Ohuchi H, Noji S, Nohno T: Truncated
type II receptor for BMP-4 induces secondary axial structures
in Xenopus embryos. Biochem Biophys Res Commun 1995,
216:26–33.
25. Newman JH, Wheller L, Lane KB, Loyd E, Ghaddipatti R, Phillips
JA, Loyd JE: Mutations in the gene for bone morphogenetic
protein receptor II as a cause of primary pulmonary hyperten-
sion in a large kindred. N Engl J Med 2001:in press.
26. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA,
Newman JH: Genetic anticipation and abnormal gender ratio
at birth in familial primary pulmonary hypertension. Am J
Respir Crit Care Med 1995, 152:93–97.
27. Lanska DJ: George Huntington (1850–1916) and hereditary
chorea. J Hist Neurosci 2000, 9:76–89.
28. Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda
T, Miyazono K: BMP type II receptor is required for gastrulation
and early development of mouse embryos. Dev Biol 2000,
221:249–258.
29. Willette RN, Gu JL, Lysko PG, Anderson KM, Minehart H, Yue T:
BMP-2 gene expression and effects on human vascular
smooth muscle cells. J Vasc Res 1999, 36:120–125.
30. Nakaoka T, Gonda K, Ogita T, Otawara-Hamamoto Y, Okabe F,
Kira Y, Harii K, Miyazono K, Takuwa Y, Fujita T: Inhibition of rat
vascular smooth muscle proliferation in vitro and in vivo by
bone morphogenetic protein-2. J Clin Invest 1997, 100:2824–
2832.
31. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder
RM: Monoclonal endothelial cell proliferation is present in
primary but not secondary pulmonary hypertension. J Clin
Invest 1998,  101:927–934.
32. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM:
Microsatellite instability of endothelial cell growth and apop-
tosis genes within plexiform lesions in primary pulmonary
hypertension. Circ Res 2001, 88:E2–E11.
33. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y,
Meyrick B: Pulmonary artery adventitial changes and venous
involvement in primary pulmonary hypertension. Am J Pathol
1995, 146:389–397.
Available online http://respiratory-research.com/content/2/4/193
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h